

Company Overview

Orgenesis is a pioneering global biotech company which is unlocking the full potential of personalized therapies and closed processing systems through its Cell & Gene Therapy Biotech Platform, with the ultimate aim of providing life changing treatments at the point of care (POCare) to large numbers of patients at low cost. The Platform consists of: (a) POCare Therapeutics, a pipeline of licensed cell and gene therapies (CGTs), and proprietary scientific knowhow; (b) POCare Technologies, a suite of proprietary and in-licensed technologies which are engineered to create customized processing systems for affordable point of care therapies; and (c) POCare Network, a collaborative, international ecosystem of leading research institutes and hospitals committed to clinical development and supply of CGTs at the point of care. By combining science, technologies and a collaborative network, Orgenesis is able to identify the most promising new therapies and provide a pathway for them to reach patients more quickly, more efficiently and at scale, thereby unlocking the power of cell and gene therapy for all.

Orgenesis Third Quarter 2020 Revenue Increases 40% Reflecting Continued Progress of POCare Platform

Nov 5 2020, 8:30 AM EST

Stock Overview

Symbol	ORGS
Exchange	Nasdaq
Market Cap	107.38m
Last Price	\$4.86
52-Week Range	\$2.35 - \$8.20

11/30/2020 04:00 PM EST

Investor Relations

Crescendo Communications, LLC
David K. Waldman
T: (212) 671-1020
orgs@crescendo-ir.com

Management Team

Vered Caplan

President, Chief Executive Officer and Chairperson

Neil Reithinger, CPA

Chief Financial Officer, Secretary, and Treasurer

Frédéric Tonglet

General Manager, Orgenesis, Belgium

Evan Fishman

Chief Financial Officer, Orgenesis LTD

Peter Molloy

Executive Vice President, Corporate Development

Efrat Assa-Kunik (PhD)

General Manager, Orgenesis Ltd.

Orgenesis Inc.

Orgenesis Inc. (Corporate Headquarters)
20271 Goldenrod Lane
Germantown, MD 20876
USA

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.